Decoy receptor 3 (DcR3), a member of the tumor necrosis factor (TNF) receptor superfamily, is known to be involved in cell survival and osteoclast (OC) formation. In this study, we show that malignant plasma cells and T lymphocytes from multiple myeloma (MM) bone disease patients, as well as Karpas 909, a human myeloma cell line, directly produce DcR3. By interacting with FasL, this molecule could inhibit OC apoptosis. In fact, the use of a neutralizing anti-DcR3 antibody induces a reduction of cell viability with a consequent increase of apoptotic cell number, the activation of caspase-8 and -3, and DNA fragmentation. Furthermore, we show that DcR3 supports OC formation in samples from MM patients through the upregulation of RANKL and TNFa by T lymphocytes and only TNFa by CD14 þ cells. In conclusion, our data provide the first evidence of the expression of DcR3 in MM, and the involvement of this molecule in supporting the survival and formation of OCs from MM bone disease patients. The production of DcR3 by T lymphocytes confers these cells a role in the pathogenesis of bone disease associated with MM.
Introduction
Bone destruction, the hallmark of multiple myeloma (MM), results from uncoupling between osteoclast (OC) and osteoblast activities. 1 OCs are activated by binding of the receptor for activation of the nuclear factor-kappa B ligand (RANKL) to its cognate receptor, RANK, whereas osteoprotegerin (OPG) acts as a naturally occurring decoy receptor that competes with RANK for the binding of RANKL. 2 Although in physiological conditions RANKL is the main cytokine driving OC formation, and is principally expressed by mesenchymal cells of the osteoblast lineage, the osteoclastogenic cytokine is produced in abundance by T cells in states of destructive osteolytic bone disease associated with MM, as well as other pathologies with bone involvement. [3] [4] [5] [6] [7] It has long been recognized that infection, inflammation and auto-immune disorder are associated with systemic and local bone loss, [5] [6] [7] and recently several groups have shown a link between T cells and the development of osteolysis associated with malignancy. 3, 4, 8 Consistently, we showed earlier an important role of T cells in supporting the formation and survival of OCs in peripheral blood mononuclear cells (PBMCs) from MM patients with osteolysis. 3 The long lifespan in our culture system occurred despite high levels of apoptotic molecules, including TRAIL and FasL. In the same paper, we showed that TRAIL was bound and inactivated by its soluble ligand, OPG, which was highly expressed by T cells in our culture system. Although the inactivation of TRAIL-mediated apoptosis of OCs was shown by the formation of the OPG-TRAIL immunocomplex, the question why FasL failed to induce OC apoptosis remained open. The primary aim of this paper was to address this issue. In addition, in MM other molecules, such as tumor necrosis factor-a (TNFa) can also contribute to OC formation and survival. TNFa enjoys a potent synergistic relationship with RANKL, but whether TNFa alone can trigger OC differentiation is controversial. Although Lam et al. 9 reported that TNFa is incapable of inducing the OC precursor to differentiate unless attended by permissive levels of, or primed by, RANKL, other groups found that in vitro the inflammatory cytokine is capable of osteoclastogenesis in the absence of RANK signaling. 10, 11 TNFa targets two membrane receptors, but its osteoclastogenic properties are mediated by TNF receptor type 1 (TNF-R1). 12 Furthermore, very recent data showed that decoy receptor 3 (DcR3), belonging to the TNFR superfamily, plays a role in the differentiation of OCs. 13 The same authors showed that by inducing the release of TNFa, DcR3 can induce OC formation from human monocytes, murine RAW264.7 macrophages and bone marrow (BM) cells. Later, it was also reported that DcR3 transgenic mice show a decreased bone mineral density, bone mineral content, and bone volume, accompanied by an increased OC formation, suggesting that in vivo the DcR3 may play an important role in osteolytic bone diseases.
14 In addition, the molecule was known as a decoy receptor for the FasL, and thus an inhibitor of Fasinduced apoptosis. 15 Although DcR3 is overexpressed in several types of cancer cells, [15] [16] [17] [18] its expression in MM has not yet been investigated. Overexpression of DcR3 in tumors may be beneficial in terms of protecting the cells against the cytotoxic and regulatory effects of FasL, 15 LIGHT 19 and TNF-like molecule 1A. 20 In MM bone disease patients, both OCs and tumor cells are resistant to apoptosis. Hence, considering the role of DcR3, as an inhibitor of Fas-induced apoptosis and inducer of osteoclastogenesis, together with the recently reported role of T cells and their products, as key regulators of OC formation, lifespan and activity, we speculated that DcR3 might contribute to the pathogenesis of MM bone disease by downregulating apoptosis and upregulating the formation of OCs from MM patients. The primary focus of this study was the potential involvement of DcR3 in the inhibition of Fas-mediated OC apoptosis, and our secondary focus was assessment of the role of DcR3 in the regulation of osteoclastogenesis in MM bone disease patients.
Materials and methods

Patients
The samples included peripheral blood (PB) and BM aspirate from 32 patients (mean age: 60 years; range: 55-78 years) diagnosed as having MM with osteolytic disease. All patients underwent total body X-rays to identify the presence of osteolytic bone lesions and/or diffuse osteoporosis. Patients whose standard X-rays were negative underwent magnetic resonance imaging scans. Bone disease was defined on the basis of the presence of one or more lesions that appeared on the X-rays or magnetic resonance imaging scan. The controls included PB and BM aspirate from 32 subjects with monoclonal gammopathy of uncertain significance (MGUS), matched for age and sex, and showing normal bone mass. BM aspirates were obtained from the iliac crest after informed consent was given, according to the tenets of the Declaration of Helsinki. 
Human myeloma cell lines and myeloma cells
Karpas 909 cells, a human myeloma cell line (HMCL), were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco Invitrogen, Milan, Italy). Primary myeloma cells were isolated from BM aspirate on a magnetic cell sorting separator (Miltenyi Biotec, Bergisch-Gladbach, Germany) using magnetic microbeads coupled to anti-CD138 monoclonal antibody (mAb). Only samples with a purity of more than 97%, checked by flow cytometry, were considered. Fresh CD138 þ MM cells were immediately analyzed and lysed after purification.
CD2-and CD14-positive cells
The CD2 þ cells from PB and BM mononuclear cells (MNCs) of controls and MM patients, were purified as described earlier.
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CD2 þ cells were treated for 24 h with 50 and 100 ng/ml rh-DcR3 (R&D Systems Inc., Minneapolis, MN, USA) and mRNA and cellular proteins were extracted. CD14 þ cell isolation was performed using a negative isolation kit (Dynal, Lake Success, NY, USA). Only cell populations with purity above 99.5% were used for experiments. CD14 þ cells, treated with 50 or 100 ng/ml rh-DcR3 for 24 h, were lysed for mRNA and protein extraction. CD14 þ cells were also used to perform osteoclastogenesis experiments.
Osteoclast formation, bone resorbing activity and cell viability
The OCs were obtained from CD14 þ cells, freshly isolated from the patients, and unfractionated PBMCs and BMMNCs of the MM patients and the controls as described earlier. 3 For some experiments, PBMCs and BMMNCs were cultured in the presence of anti-DcR3 mAb (0.2-0.8 mg/ml; R&D Systems Inc.) or anti-immunoglobulin G (IgG) control antibody (Ab). Mature OCs were identified as Tartrate-resistant acid phosphatasepositive (TRAP þ ) (Sigma-Aldrich, Milan, Italy) cells containing three or more nuclei. For some experiments, CD14 þ cells were cultured in the presence of 25 ng/ml macrophage colonystimulating factor (MCSF), 100 ng/ml DcR3, 30 ng/ml TNFa and TNF-R1Fc (range: 1-20 ng/ml; R&D Systems Inc.) or RANKFc (100 ng/ml; R&D Systems Inc.) or with anti-IgG control Ab. Osteoclastogenesis experiments were also performed with or without 0.4 mg/ml anti-DcR3 mAbs in coculture systems between CD14 þ and T or CD138 þ cells. Resorbing assay was performed on OCs derived from CD14 þ cells plated on Millennium Osteologic slices (Millennium Biologix, Kingston, ON, Canada) in the presence of DcR3 as described elsewhere. 3 Cell viability was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described earlier 3 on OCs in the presence of anti-DcR3 (0.2-1 mg/ml), 23 and on CD138 þ or bone marrow stromal cells in the presence of DcR3 with or without FasL.
RNA isolation and real-time PCR
The RNA extraction and cDNA amplification were performed as described earlier. 3 cDNA was amplified with the iTaq SYBR Green supermix with ROX kit (Bio-Rad Laboratories, Bio-Rad Laboratories Inc., Hercules, CA, USA) and the PCR amplification was performed using the Chromo4 Real-Time PCR Detection System (Bio-Rad Laboratories). The running conditions were as follows: incubation at 95 1C for 3 min, and 40 cycles of incubation at 95 1C for 15 s and 60 1C for 30 s. After the last cycle, the melting curve analysis was performed into 55-95 1C interval by incrementing the temperature of 0.5 1C. The fold change values were calculated by Pfaffl's method. 24 
Western blot analysis
Protein samples (50 mg) were subjected to electrophoresis. The following primary Abs were used: mouse anti-DcR3 and anti-RANKL (R&D Systems Inc.), anti-caspase-8 and anticaspase-3 (Cell Signaling, Technology Inc., Danvers, MA, USA), and anti-b actin, rabbit anti-TNFa and anti-FasL (sc-6237) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). To detect the DcR3-FasL complex, immunoprecipitation of fresh T-cell lysates (150 mg) of PBMCs from MGUS and MM patients, and 1 mg of the media from PBMCs from the same subjects collected at day 10 and day 21 of cultures was performed using anti-FasL mAb or IgG, as described earlier. 3 
DAPI staining and DNA fragmentation
The OCs, treated with anti-DcR3 mAb (0.2-1 mg/ml) for 48 h, were subjected to DAPI staining and DNA fragmentation as described before. 25 
Statistical analyses
Statistical analyses were performed by Student's t-test with the Statistical Package for the Social Sciences (SPSSX/PC) software (SPSS, Chicago, IL, USA). The results were considered statistically significant for P o0.05. (Figure 1b) . To establish whether DcR3 can bind FasL, we performed immunoprecipitation with anti-FasL mAb on T-cell lysates and media from OCs generated from PBMCs of MM patients collected after 10 and 21 days of culture. Results showed the formation of a DcR3-FasL immunocomplex in both T-cell lysates and culture media from MM patients. The DcR3-FasL immunocomplex, identified as a band of about 33 kDa, was not found in media from samples of MGUS patients (Figure 1c ), or media from T-cell-depleted MM PBMC cultures (not shown).
Results
DcR3 expression by pre-and mature OCs, T and plasma cells from MM patients
DcR3 role on OC survival
Once OCs were completely differentiated in culture, the cell viability and the number of apoptotic cells were determined.
OCs incubated for 48 h with increasing concentrations of antiDcR3-neutralizing Ab (0.2-1 mg/ml) showed a significant dosedependent reduction of their viability, and a decrease of about 30% was reached at the highest concentration of the Ab (Figure 2a ). The number of apoptotic cells was evaluated, in the same experimental conditions, by counting the cells after DAPI staining. The nuclei of apoptotic cells were condensed and fragmented, whereas the nuclei of non-apoptotic cells were round and smooth. Only multinucleated cells showing condensed chromatin were counted as apoptotic. The percentage of apoptotic cells in control conditions was 3.6%, corresponding to 9 ± 2 cells, with respect to 100%, arbitrarily assigned to the total number of OCs present onto coverslips that was 250 ± 15.
Results showed that the percentage of apoptotic cells was 12.8%, (32 ± 2. 
Effect of DcR3 on the survival of plasma cells and BM stromal cells in the presence of FasL
Cell survival, by MTT assay, has been studied in CD138 þ and BM stromal cells from marrow aspirates of MM bone disease patients to evaluate the effect of DcR3 in the presence of FasL. The cells have been cultured in the presence of 10 ng/ml FasL with or without 100 ng/ml DcR3 and we found that FasL reduces 20 ± 2 and 25 ± 4% the viability of CD138 þ and BM stromal cells, respectively; the reduction of cell survival exerted by FasL was restored by DcR3 addition (not shown).
Neutralization of DcR3 activates caspase-8 and -3 in mature OCs
To better characterize the effect of DcR3 neutralization on OC apoptosis, we investigated the activation of the caspase cascade in OCs treated with anti-DcR3-neutralizing Ab. In particular, the activation of caspase-8 and -3 was analyzed. We showed that both cleavages of casapase-8 occurred in OCs from MM patients treated with anti-DcR3 mAb, but not anti-IgG control Ab. In particular, the generation of intermediate forms could be clearly observed already after 1 h treatment, and after 2 h the second cleavage took place, inducing marked formation of the p23 Role of DcR3 in multiple myeloma bone disease S Colucci et al active caspase fragment. Furthermore, we showed the activation of caspase-3 starting from 1 h and reaching maximum activation after 4 h of treatment (Figure 2d ).
DcR3 involvement in the formation of OCs from MM patients
By adding increasing concentrations of a neutralizing anti-DcR3 mAb (ranging from 0.2 to 0.8 mg/ml) to the media of unfractionated and unstimulated PBMCs and BMMNCs from MM patients with osteolysis, we showed a dose-dependent inhibition of osteoclastogenesis in both the culture systems. The inhibition exerted by the mAb was rather different in the two cell cultures. In particular, in PBMCs 0.4 mg/ml anti-DcR3 mAb induced a strong inhibition of OC formation (Figure 3a) , whereas in BMMNCs the same dosage of the mAb reduced the osteoclastogenesis by about 50%, and 0.8 mg/ml anti-DcR3 mAb induced the maximum inhibition and a residual OC formation still persisted (Figure 3b) . No effect was exerted on osteoclastogenesis by anti-IgG control Ab. No spontaneous osteoclastogenesis occurred in PBMCs and BMMNCs of MGUS patients, thus the effect of anti-DcR3 was not tested in these systems. In addition, to determine the contribution of DcR3 by purified T or CD138 þ cells on OC formation, we performed osteoclastogenesis experiments in coculture systems between CD14 þ and T or CD138 þ cells. As shown in the Figure 3c , the presence of anti-DcR3 significantly reduced the OC formation in both coculture systems; however, the inhibition was highly efficient in the presence of T cells with respect to CD138 þ cells.
DcR3 induces RANKL and TNFa release by T cells and monocytes
We analyzed the expression of TNFa and RANKL in unfractionated PBMCs incubated for 24 h with or without increasing concentrations of anti-DcR3 mAb by real-time PCR and western blot. We found elevated mRNA levels of TNFa and RANKL in untreated PBMCs from MM patients with respect to the same cultures from MGUS patients, utilized as control, and reduced levels of both cytokines in the presence of the anti-DcR3 mAb (Figure 4a ). In addition, the inhibition exerted by the anti-DcR3 mAb on the expression of both cytokines was shown at protein levels ( Figure 4b ). To characterize the specificity of this effect, unfractionated PBMCs, purified T and CD14 þ cells from MM patients were treated with DcR3 and analyzed for TNFa and RANKL expression. We found that TNFa and RANKL mRNA levels were 4.0 ± 0.2-and 3.5 ± 0.3-fold increased, respectively, when unfractionated PBMCs were treated with 100 ng/ml DcR3 (data not shown). In particular, by real-time PCR we showed that DcR3 upregulated the basal levels of TNFa in both T and CD14 þ cells. The treatment with 50 and 100 ng/ml DcR3 induced a dose-dependent increase of TNFa in both cell types, whereas RANKL expression was upregulated by the same dosages only in T cells (Figure 4c ) and no expression was found in CD14 þ cells (not shown). The expression of both cytokines at protein levels overlapped the results of mRNA expression (Figure 4d ). The demonstration of a DcR3-dependent upregulation of TNFa in purified CD14 þ cells prompted us to investigate whether a TNFa-related OC formation could take place in a RANKL-independent manner in MM CD14 þ cells. For this purpose, we performed osteoclastogenesis experiments in the presence of DcR3 on purified CD14 þ cells from MM Role of DcR3 in multiple myeloma bone disease S Colucci et al patients. As shown in Figure 5a , DcR3 stimulated osteoclastogenesis of CD14 þ cells in a dose-dependent manner, but it did not affect the number of OC precursors evaluated by MTT assay in MM CD14 þ cells treated for 48 h with 100 ng/ml DcR3 (data not shown). The OCs formed in the presence of DcR3 were functional as shown by resorbing assay showed in the Figure 5b . Interestingly, the DcR3-induced OC formation was similar to what observed with TNFa and slightly lower than in the presence of RANKL. The major number of OCs obtained in the presence of RANKL could be because of the synergistic effect of very few amount of TNFa produced by CD14 þ cells. Moreover, the TNFa-induced OC formation occurred in a RANKLindependent manner as shown by the simultaneous presence of TNFa and RANK-Fc (Figure 5c ). Finally, the DcR3-induced OC formation was abrogated by TNFR1-Fc (ranging from 1 to 20 ng/ml), whereas it was not inhibited by RANK-Fc or an antiIgG control Ab (Figure 5c ). The number of pre-OC was not affected by TNFR1-Fc as shown by MTT assay in MM CD14 þ cells treated with TNFR1-Fc (ranging from 1 to 20 ng/ml) for 48 h (data not shown).
Discussion
In an earlier study, we showed that OCs from MM patients with osteolysis displayed a long lifespan in culture, despite high levels of apoptotic molecules, including TRAIL and FasL. 3 Although the inactivation of TRAIL-mediated apoptosis of OCs was shown by the formation of the OPG-TRAIL immunocomplex, the question why FasL was not active in inducing the OC apoptosis remained open. Thus, in line with the primary aim of our study, herein, we investigated whether FasL could be bound and inactivated by any other molecule/s secreted by cells present in our culture system. This study suggests that DcR3 contributes to the longer survival of MM OCs possibly through the interaction with FasL. These findings are firstly supported by the demonstration that DcR3 was expressed by freshly prepared ex vivo T and plasma cells from MM patients, and by the formation of the FasL-DcR3 immunocomplex that we observed in the cultures. These data suggest that, as in other tumors, [26] [27] [28] overexpression of DcR3 also takes place in MM and could be responsible for the resistance to FasL-mediated OC apoptosis. In fact, using a neutralizing DcR3 mAb in OCs from PBMCs of MM patients, we showed that DcR3 inactivation was associated with an increased OC apoptosis, as shown by the reduction of OC viability, the increased number of apoptotic OCs and the increased DNA ladder formation. With the aim of better characterizing the mechanism by which DcR3 inhibits OC apoptosis, we showed that differentiated OCs, treated with antiDcR3 mAb, showed the activation of caspase-8 and -3, corresponding to the typical apoptotic pathway induced by FasL. 29 Our findings strongly suggest that DcR3 could be involved in the protection of OCs against death through Fasinduced apoptosis. Furthermore, finding that DcR3 displays an inhibitory effect on the survival of MM and bone marrow stromal cells in the presence of FasL, its role in the inhibition of FasL-mediated apoptosis seems not to be limited to OCs. Although other mechanisms, including upregulation of inflammatory cytokines and/or interaction with other ligands, can occur as well, our evidences are consistent with literature data reporting that DcR3 can bind FasL, and may act as an inhibitor of FasL-induced cell death. 15, 16, 30 This is an important point considering that FasL-mediated apoptosis is the most common physiological form of cell death, and occurs during embryonic development, tissue remodeling, immune regulation and tumor regression. Abnormalities in the FasL system and the overexpression of DcR3 associated with a resistance to FasLmediated apoptosis can result in a number of human pathological conditions, including tumors. 31, 32, [26] [27] [28] In many cancers, a mechanism allowing cells to escape the immune surveillance of the host 31 and conferring protection against FasL-induced apoptosis is triggered by the secretion of molecules, including DcR3, able to inactivate the apoptotic ligands.
In this paper, we second showed that DcR3, produced by both MM and T cells, contributed to the formation of OCs in PBMCs and BMMNCs from MM patients as shown by a dosedependent inhibition of osteoclastogenesis in the presence of the neutralizing anti-DcR3 mAb in both culture systems. However, the effect exerted by the mAb was rather different; Role of DcR3 in multiple myeloma bone disease S Colucci et al in particular, in PBMCs a complete inhibition of OC formation was obtained, whereas in BMMNCs, a residual OC formation still persisted although higher concentrations of the Ab were utilized. The results obtained in the BM cultures could be attributable to the greater complexity of BM compared with PB cultures, the presence of other cytokines that could additionally and/or alternatively be able to influence OC formation and activity cannot be excluded. 33, 34 Our results were also supported and more clarified by the data obtained in coculture systems consisting of CD14 þ and T cells from PB, and CD14 þ Figure 4 Effect of DcR3 on TNFa and RANKL production by PBMCs, CD14 þ and T cells. PBMCs from MGUS and MM patients, treated for 24 h with or without anti-DcR3 mAb, were analyzed for TNFa and RANKL expression by real-time PCR (a) and western blot (b) analysis. Expression of TNFa and RANKL at mRNA and protein levels was also analyzed in MM T and CD14 þ cells treated for 24 h with DcR3 and western blot (c-d). The intensity of the bands obtained by western blot was quantified by densitometry (histograms) and normalized to b-actin (*Po0.01; **Po0.001). The histograms represent the mean values±s.e. of five independent experiments, whereas the blots correspond to one representative experiment. and CD138 þ cells from BM of MM patients. In both cocultures, the addition of anti-DcR3 mAb reduced the OC formation, however, the effect of the mAb was less efficient in the cocultures in which CD14 þ cells were in the presence of CD138 þ cells suggesting that, besides DcR3, CD138 þ cells can produce other molecules contributing to the osteoclastogenesis. These findings were in agreement to what observed in BMMNC cultures in which CD14 þ , T and CD138 þ cells are simultaneously present. Moreover, we showed earlier that MM T cells produced large amounts of RANKL, but the mechanism inducing the RANKL expression by T cells remained unclear. 3 Herein, we showed that DcR3 could be one of the cytokines responsible for RANKL production by T cells. We first showed that stimulation of MM PBMCs by DcR3 upregulated the expression of RANKL and TNFa. Second, we showed a direct effect of DcR3 on purified T and CD14 þ cells. We showed that DcR3 upregulated TNFa expression in both T and CD14 þ cells, whereas RANKL was upregulated by the molecule only in T cells. These findings suggest that DcR3, produced by T cells, may have an autocrine effect by increasing the TNFa and RANKL basal levels, whereas it may exert a paracrine activity on CD14 þ cells, inducing only TNFa release. The release of TNFa was not involved in DcR3 effect on OC survival, we showed in the first part of the work, as the presence of TNFR1-Fc did not affect OC viability. Moreover, we showed the effect of DcR3 on osteoclastogenesis in purified CD14 þ cells, showing that the addition of DcR3 dose-dependently induced the formation of OCs. This is in line with literature data showing that DcR3 can induce osteoclastogenesis in human monocytes, murine RAW264.7 macrophages and BM cells. 13 Conversely, in rheumatoid arthritis Edwards et al. 35 showed that DcR3 alone had no effect on osteoclastogenesis while it inhibited the LIGHT-induced OC formation. The discrepancy with our findings could be explained by both the different culture models originating from patients with dissimilar pathology, and the diverse DcR3 dosages utilized in the experiments. In addition, we showed that the action of DcR3 in inducing OC formation by CD14 þ cells occurred through TNFa in a RANKL-independent manner and not because of increased number of OC precursors. This conclusion was proven by the use of TNFR1-Fc, antagonizing one of the TNFa receptors, which abrogated DcR3-stimulated osteoclastogenesis by CD14 þ cells without interfering with the number of OC precursors. However, it is important to consider that although TNFa action is independent of RANKL, it is also known to be strongly boosted by RANKL. For example, a minuscule amount of RANKL is sufficient to synergize with TNFa to promote osteoclastogenesis by precursor cells. 9 Given the synergy between TNFa and RANKL, and our data showing the lack of inhibition of DcR3 effect by RANK-Fc, we suggest that the marked effect of DcR3 on osteoclastogenesis by CD14 þ cells may be a TNFa-mediated direct effect.
Conclusion
In conclusion, the results described in this paper clearly suggest that DcR3, originating from both MM and T cells, may contribute to the stimulation of OC activity by decreasing apoptosis and increasing the formation of OCs. This is the first report showing a possible role of DcR3 and its ability to stimulate OC activity in MM through the inactivation of FasLinduced OC apoptosis, and to increase osteoclastogenesis through the release of TNFa and RANKL. As the effect of DcR3 in the stimulation of OC formation was not totally reversed by the Ab against DcR3 in BM cultures, we cannot exclude the possible participation of other factor/s not considered in this study. Therefore, given the potential role of DcR3 in MM bone disease, the DcR3 signaling pathway, as well as its target ligands in monocytes, may be of clinical value in treating myeloma bone disease patients. Role of DcR3 in multiple myeloma bone disease S Colucci et al
